A tale of 2 investment managers
There were positive trading updates from companies covered here, including a couple of relative newcomers to AIM, as well as two investment managers commanding very different valuations. (Free to read)
Cambridge Cognition: major new pharma client
Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, has been awarded contracts for two clinical trials by a top 20 pharmaceutical company to assess the pro-cognitive effects of a new drug in schizophrenia. Together the contracts are worth £700,000 over two years.
This is the second pharmaceutical client to award Cambridge Cognition major contracts for cognitive assessments for schizophrenia in…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article